Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARAND-X: Maraviroc Switch in HIV-positive Patients With HAND
NCT03163277Phase 4Terminated
- Start
- May 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of maraviroc in HIV-associated neurocognitive disorder (HAND). Primary endpoint: Global Deficit Score at 6 months. Started May 2017; status: terminated.
02
Drugs
maraviroc
03
Conditions
HIV-associated neurocognitive disorder (HAND)
Beyond the preview
Go deeper on NCT03163277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163277.